TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT06909877

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing HH2853 Tablets for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

HH2853 Tablets (DRUG): 25mg, 100mg and 200 mg BID oral administration

Drugs / treatments
HH2853 Tablets
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT06909877

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1, Phase 2 trial is testing HH2853 Tablets for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

HH2853 Tablets (DRUG): 25mg, 100mg and 200 mg BID oral administration

Drugs / treatments: HH2853 Tablets

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 100 patients

Primary endpoint: Phase Ib: To determine the RP2D of HH2853 in PTCL patients; Phase II: To evaluate the efficacy of HH2853 of R/R PTCL patients who have received at least one prior systemic combination chemotherapy and at least one new drug

Ages: 18 Years to 75 Years

Start date: 2022-07-27 | Est. completion: 2027-07-30

Locations

0 US sites · 1 total

Contact

Haiying Jia | haiying.jia@haihepharma.com | 86-20568888

Sponsor: Haihe Biopharma Co., Ltd. (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06909877

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.